Dr. Leung Kwong Chuen, Specialist in Clinical Oncology and Clinical Associate Professor (Honorary) at the Department of Medicine and Therapeutics of the Chinese University of Hong Kong said:" SCLC is a relatively difficult subtype of lung cancer to treat and is characterized by a high degree of malignancy, 🔯poor prognosis, and high recurrence. A lack of new treatment options after recurrence of the disease is a major challenge faced in current clinical application. We are very pleased🐼 to see eligible patients are able to receive this innovative therapy through this program and improve their prognosis."
Dr. Au Siu Kie, Specialist in Clinical Oncology and President of the Hong Kong Precision Oncology Society said:" Lung cancer is the leading cause of cancer deaths in Hong Kong. For the last 3 decades. SCLC has been notorious due to the lack of available medications. We believe 𒈔that Lurbinectedin is a breakthrough and will be able to provide a better treatment option for patients with relapse SCLC."
Andy Siow, APAC Regional Director of Luye Pharma (International), said:” Luye Pharma has been committed to developing, manufac📖turing and commercializing innovative anticancer drugs to address unmet clinical needs. ✨The Named Patient Program will help to provide immediate access to Lurbinectedin for those with urgent healthcare needs, bringing hope to patients with SCLC who are suffering from the disease."
William Van, General Manager, Abacus Medicine Pharma Services Asia Limited, said:” We are glad to enter into this distribution partnership with Luye Pharma for Lurbinectedin and the Named Patient Program in Hong Kong. Leveraging extensive experience in running such progra⛎ms, in addition to our comprehensive local business network and channel strengths, we are looking forward to working closely with each other to provide better service to local pat🎀ients.”
In addition to Hong Kong, Lurbinectedin is also available to patients in the Chinese mainland for urgent clinical use at designated medical institutions in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.